Oct 07, 2016 7:00 am EDT Heat Biologics Substantially Reduces Debt and Reports Proceeds of Approximately $2.8 Million Year-to-Date from the Exercise of Warrants
Sep 14, 2016 7:00 am EDT Heat Biologics Resumes Enrollment in its Non-Small Cell Lung Cancer Trial Evaluating HS-110 in Combination with Anti-PD-1 Checkpoint Inhibitor
Aug 15, 2016 4:15 pm EDT Heat Biologics Provides Corporate Update and Reports Second Quarter 2016 Financial Results
Jul 22, 2016 8:00 am EDT Heat Biologics Announces Suspension of Proposed Public Offering of Common Stock
Jul 07, 2016 7:00 am EDT Heat Biologics Announces “Cancer Immunology Research” Publication Featuring its ComPACT Platform Technology
Jun 06, 2016 7:00 am EDT Heat Biologics Presents a Poster on its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial at ASCO Annual Meeting
Apr 26, 2016 7:00 am EDT Heat Biologics to Present at PIONEERS 2016, Presented by Joseph Gunnar & Co.